Velpanat Use In Pregnancy & Lactation

Pregnancy: There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of sofosbuvir, velpatasvir or Sofosbuvir and Velpatasvir tablets in pregnant women.
Sofosbuvir: Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions).
It has not been possible to fully estimate exposure margins achieved for sofosbuvir in the rat relative to the exposure in humans at the recommended clinical dose (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Velpatasvir: Animal studies have shown a possible link to reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions).
As a precautionary measure, Sofosbuvir and Velpatasvir tablets use are not recommended during pregnancy.
Breast-feeding: It is unknown whether sofosbuvir, metabolites of sofosbuvir or velpatasvir are excreted in human milk.
Available pharmacokinetic data in animals have shown excretion of velpatasvir and metabolites of sofosbuvir in milk.
A risk to the newborns/infants cannot be excluded. Therefore, Sofosbuvir and Velpatasvir tablets should not be used during breast-feeding.
Fertility: No human data on the effect of Sofosbuvir and Velpatasvir tablets on fertility are available. Animal studies do not indicate harmful effects of sofosbuvir or velpatasvir on fertility.
If ribavirin is co-administered with Sofosbuvir and Velpatasvir tablets, refer to the Prescribing information for ribavirin for detailed recommendations regarding pregnancy, contraception, and breast-feeding.